AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20522508 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardening
Number of subjects: 30
Study 20522508 — intervention group
Group type: COMPARATOR
Intervention: Reading (Control)
Number of subjects: 30
Study 19196482 — intervention group
Group type: EXPERIMENTAL
Intervention: Beach-based intervention promoting sunless tanning, including sun damage imaging and sun safety recommendations.
Number of subjects: 250
Study 19196482 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire only control group.
Number of subjects: 250
Study 19196482 — intervention group
Group type: EXPERIMENTAL
Intervention: Beach-based intervention promoting sunless tanning.
Number of subjects: 250
Study 16495695 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous local ablative therapy (PLAT)
Number of subjects: 180
Study 16495695 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 180
Study 12795812 — intervention group
Group type: EXPERIMENTAL
Intervention: APV600/RTV BID
Number of subjects: 211
Study 12795812 — intervention group
Group type: COMPARATOR
Intervention: APV1200 BID
Number of subjects: 211
Study 10695534 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ionic contrast medium (3.0 (1.2‐6.8) mls/kg)
Number of subjects: 23
Study 10695534 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ionic contrast medium
Number of subjects: 23
Study 10695534 — intervention group
Group type: COMPARATOR
Intervention: Control (Acyanotic subjects)
Number of subjects: 23
Study 9347370 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated, pressure-regulated, volume-controlled ventilation (PRVC)
Number of subjects: 60
Study 9347370 — intervention group
Group type: COMPARATOR
Intervention: Intermittent mandatory ventilation (IMV)
Number of subjects: 60
Study 8248660 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (specific types not mentioned)
Number of subjects: 0
Study 8248660 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3942665 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique A: I:E ratio 0.43, driving pressure 2.9 bar, no PEEP
Number of subjects: 7
Study 3942665 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique B: I:E ratio 1.0, driving pressure 1.9 bar, no PEEP
Number of subjects: 7
Study 3942665 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique C: I:E ratio 0.43, driving pressure 1.8 bar, PEEP 11 cm H2O
Number of subjects: 7
Study 3942665 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques (A, B, C)
Number of subjects: 7
Study 31573387 — intervention group
Group type: EXPERIMENTAL
Intervention: Insoluble yeast β‐glucan (250 mg, 250 mL/day)
Number of subjects: 318
Study 31573387 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble yeast β‐glucan (250 mg, 250 mL/day)
Number of subjects: 318
Study 31573387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 29361920 — intervention group
Group type: EXPERIMENTAL
Intervention: OA‐CAT Functional Difficulty scale
Number of subjects: 0
Study 29361920 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS® Physical Function CAT
Number of subjects: 0
Study 27301941 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week caregiver-mediated exercises program with e-health support
Number of subjects: 63
Study 25479348 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic data capture (EDC)
Number of subjects: 150
Study 25479348 — intervention group
Group type: COMPARATOR
Intervention: Paper-based questionnaire (QNN)
Number of subjects: 150
Study 22090363 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral losmapimod 7.5 mg twice daily
Number of subjects: 302
Study 22090363 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol/fluticasone propionate 50 µg/500 µg combination (SFC)
Number of subjects: 302
Study 22090363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 20384393 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg single oral dose in ESRD patients
Number of subjects: 463
Study 20384393 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 20-60 mg once or twice daily in phase II/III trials
Number of subjects: 463
Study 20384393 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine in ESRD patients
Number of subjects: 463
Study 18727457 — intervention group
Group type: COMPARATOR
Intervention: 7-day standard triple therapy
Number of subjects: 65
Study 18727457 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day triple therapy plus L. reuteri
Number of subjects: 65
Study 18727457 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day triple therapy plus probiotic mixture
Number of subjects: 65
Study 18727457 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day standard triple therapy plus probiotic mixture
Number of subjects: 65
Study 15999046 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group (1 g of methylprednisolone before surgery and 4 mg of dexamethasone every 6 hours for 1 day after surgery)
Number of subjects: 88
Study 15999046 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 88
Study 15999046 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group
Number of subjects: 88
Study 15999046 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 12379550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (0.27 ppm)
Number of subjects: 12
Study 12379550 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 12
Study 10636535 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban and enoxaparin (n=26)
Number of subjects: 55
Study 10636535 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban and enoxaparin
Number of subjects: 55
Study 10636535 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban and unfractionated heparin (n=27)
Number of subjects: 55
Study 10636535 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban and unfractionated heparin
Number of subjects: 55
Study 8943976 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 626
Study 1758395 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP
Number of subjects: 40
Study 1758395 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40
Study 1758395 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP and Acupuncture
Number of subjects: 40
Study 1758395 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 40
Study 7181738 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet with 400 mg cholesterol and 0.8 polyunsaturated-to-saturated fat ratio
Number of subjects: 6494
Study 7181738 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 6494
Study 31602471 — intervention group
Group type: EXPERIMENTAL
Intervention: WW + OT (Weight Watchers plus OnTrack)
Number of subjects: 181
Study 31602471 — intervention group
Group type: COMPARATOR
Intervention: WW (Weight Watchers)
Number of subjects: 181
Study 27495968 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgery plus standard voice therapy
Number of subjects: 150
Study 27495968 — intervention group
Group type: COMPARATOR
Intervention: Voice Therapy Expulsion
Number of subjects: 150
Study 25847554 — intervention group
Group type: EXPERIMENTAL
Intervention: Black seeds (1.5g/day)
Number of subjects: 250
Study 25847554 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric (2.4g/day)
Number of subjects: 250
Study 25847554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (900mg Black seeds and 1.5g Turmeric/day)
Number of subjects: 250
Study 23545664 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 26
Study 23545664 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan
Number of subjects: 26
Study 21443724 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive rectal painful distention (RRD)
Number of subjects: 27
Study 21443724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous CRF (100 µg)
Number of subjects: 27
Study 21443724 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 27
Study 21443724 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) ratings
Number of subjects: 27
Study 19234822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg IV ramosetron
Number of subjects: 120
Study 19234822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg oral ramosetron
Number of subjects: 120
Study 19234822 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 120
Study 15738933 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment phone contact (experimental group)
Number of subjects: 20
Study 15738933 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study 12423848 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble gel lubricant
Number of subjects: 8534
Study 12423848 — intervention group
Group type: COMPARATOR
Intervention: Water only (control)
Number of subjects: 8534
Study 10356008 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal prompts sent 2 weeks and 3 months after discharge from hospital.
Number of subjects: 328
Study 8608893 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Sclerotherapy (ES)
Number of subjects: 63
Study 8608893 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Number of subjects: 63
Study 8608893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TIPS and ES
Number of subjects: 63
Study 1707221 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 19
Study 1707221 — intervention group
Group type: COMPARATOR
Intervention: Metformin (placebo)
Number of subjects: 19
Study 6814470 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate (30 mg)
Number of subjects: 10
Study 6814470 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate (60 mg)
Number of subjects: 10
Study 6814470 — intervention group
Group type: EXPERIMENTAL
Intervention: +/--glaucine phosphate (60 mg)
Number of subjects: 10
Study 6814470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6814470 — intervention group
Group type: EXPERIMENTAL
Intervention: +/--glaucine phosphate (30 mg)
Number of subjects: 10
Study 31050927 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser disinfection (LD) group
Number of subjects: 84
Study 31050927 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-laser disinfection (PLD) group
Number of subjects: 84
Study 27392909 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 349
Study 27392909 — intervention group
Group type: COMPARATOR
Intervention: Conventional lipid lowering drugs (Group C)
Number of subjects: 349
Study 24721903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon α (IFNα) treatment
Number of subjects: 0
Study 24721903 — intervention group
Group type: COMPARATOR
Intervention: Untreated HDV-infected patients
Number of subjects: 0
Study 24721903 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 24721903 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD56(dim) NK cells
Number of subjects: 0
Study 23825402 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on feature difference tasks
Number of subjects: 0
Study 23825402 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on signal-in-noise tasks
Number of subjects: 0
Study 21068719 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomazenil (3.7 μg administered intravenously over 10 min)
Number of subjects: 13
Study 21068719 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 13
Study 21068719 — intervention group
Group type: COMPARATOR
Intervention: Iomazenil in healthy controls (n=20)
Number of subjects: 13
Study 18397193 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional exercise training (supervised by a physical therapist, three times weekly for 4 months)
Number of subjects: 45
Study 18397193 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 45
Study 17450980 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week, 3 days/week weight-training treatment
Number of subjects: 88
Study 17450980 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 88
Study 15177808 — intervention group
Group type: EXPERIMENTAL
Intervention: Skilled readers naming or making lexical decisions on words and pseudo-words
Number of subjects: 2
Study 15177808 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-compensated dyslexic participant in lexical decision and naming tasks
Number of subjects: 2
Study 12488953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose tolerance test
Number of subjects: 52
Study 12488953 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet-cell antibody greater than 20 JDFU
Number of subjects: 52
Study 12488953 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin autoantibodies
Number of subjects: 52
Study 12488953 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of positive autoantibodies
Number of subjects: 52
Study 9690691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone 50 mg once daily
Number of subjects: 410
Study 9690691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone 30 mg once daily
Number of subjects: 410
Study 9690691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 7642847 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina-guided medical therapy
Number of subjects: 0
Study 7642847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia-guided medical therapy
Number of subjects: 0
Study 7642847 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 0
Study 2750268 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera B subunit-whole cell vaccine (BS-WC)
Number of subjects: 0
Study 2750268 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole cell vaccine (WC)
Number of subjects: 0
Study 2750268 — intervention group
Group type: COMPARATOR
Intervention: Reference system (Vibrio cholerae Inaba E1 Tor antigenic extract)
Number of subjects: 0
Study 2750268 — intervention group
Group type: EXPERIMENTAL
Intervention: Common antigens in vaccines and Vibrionaceae strains
Number of subjects: 0
Study 1066128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinkel's modified scheme for ALL with prophylactic irradiation of the CNS
Number of subjects: 40
Study 1066128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinkel's modified scheme for ALL without prophylactic irradiation of the CNS
Number of subjects: 40
Study 1066128 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarkson's scheme for AML with prophylactic irradiation of the CNS
Number of subjects: 40
Study 1066128 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarkson's scheme for AML without prophylactic irradiation of the CNS
Number of subjects: 40
Study 31299663 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b eye drops (4 times a day for 3 months)
Number of subjects: 53
Study 31299663 — intervention group
Group type: COMPARATOR
Intervention: Control group (bare sclera technique + levofloxacin and 0.1% fluorometholone eye drops 4 times a day for 3 months)
Number of subjects: 53
Study 28330592 — intervention group
Group type: EXPERIMENTAL
Intervention: twice-weekly deep TMS (dTMS) continuation treatment for up to 12 weeks
Number of subjects: 33
Study 25956750 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX6 (oxaliplatin, leucovorin, and 5-FU for 12 cycles)
Number of subjects: 408
Study 25956750 — intervention group
Group type: COMPARATOR
Intervention: CAPOX (oxaliplatin and capecitabine for eight cycles)
Number of subjects: 408
Study 25956750 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Number of subjects: 408
Study 25956750 — intervention group
Group type: COMPARATOR
Intervention: CAPOX
Number of subjects: 408
Study 23449691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear periodized exercise (NLPE) training
Number of subjects: 110
Study 23449691 — intervention group
Group type: COMPARATOR
Intervention: Traditional endurance and progressive resistance (EPR) training
Number of subjects: 110
Study 25427330 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch adhesive (Single Bond 2)
Number of subjects: 75
Study 25427330 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement lining + Total-etch adhesive (Single Bond 2)
Number of subjects: 75
Study 25427330 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive (Clearfil SE Bond)
Number of subjects: 75
Study 25427330 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement lining + Self-etching adhesive (Clearfil SE Bond)
Number of subjects: 75
Study 25427330 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glass-ionomer cement lining)
Number of subjects: 75
Study 17804473 — intervention group
Group type: EXPERIMENTAL
Intervention: pAKT positive staining in HER2+ tumors
Number of subjects: 823
Study 17804473 — intervention group
Group type: EXPERIMENTAL
Intervention: pAKT positive staining in HER2- tumors
Number of subjects: 823
Study 17804473 — intervention group
Group type: EXPERIMENTAL
Intervention: pAKT expression in HER2-/EGFR+ tumors
Number of subjects: 823
Study 17804473 — intervention group
Group type: EXPERIMENTAL
Intervention: pAKT expression in HER2-/EGFR- tumors
Number of subjects: 823
Study 17804473 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of pAKT with prognosis
Number of subjects: 823
Study 17804473 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive value of pAKT for anthracycline resistance
Number of subjects: 823
Study 16104957 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophy brush with calcium pyrophosphate
Number of subjects: 72
Study 16104957 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophy brush with pumice
Number of subjects: 72
Study 16104957 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophy brush with Nupro coarse
Number of subjects: 72
Study 16104957 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophy brush with Hawe cleanic
Number of subjects: 72
Study 16104957 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophy cup with calcium pyrophosphate
Number of subjects: 72
Study 16104957 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophy cup with pumice
Number of subjects: 72
Study 16104957 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophy cup with Nupro coarse
Number of subjects: 72
Study 16104957 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophy cup with Hawe cleanic
Number of subjects: 72
Study 16104957 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteless prophy cup
Number of subjects: 72
Study 11950430 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose alteplase plus abciximab
Number of subjects: 70
Study 11950430 — intervention group
Group type: COMPARATOR
Intervention: Direct angioplasty plus abciximab
Number of subjects: 70
Study 10226398 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 50 mgs in divided doses with radiation (6000 cGy in six weeks)
Number of subjects: 58
Study 10226398 — intervention group
Group type: COMPARATOR
Intervention: Control group (radiation 6000 cGy in six weeks without chlorpromazine)
Number of subjects: 58
Study 10226398 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) with radiation
Number of subjects: 58
Study 7893278 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal remedy Kava-Kava
Number of subjects: 0
Study 7893278 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical homeopathy
Number of subjects: 0
Study 7893278 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary interventions
Number of subjects: 0
Study 2653876 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (double dose)
Number of subjects: 27
Study 2653876 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (sublingual)
Number of subjects: 27
Study 2653876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 178191 — intervention group
Group type: EXPERIMENTAL
Intervention: standard inpatient care
Number of subjects: 175
Study 178191 — intervention group
Group type: EXPERIMENTAL
Intervention: brief hospitalization with transitional day care
Number of subjects: 175
Study 178191 — intervention group
Group type: EXPERIMENTAL
Intervention: brief hospitalization without transitional day care
Number of subjects: 175
Study 30092456 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary disease management programme with exercise training
Number of subjects: 212
Study 30092456 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary disease management programme without exercise training
Number of subjects: 212
Study 30092456 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 212
Study 30092456 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary disease management programme for patients with contraindications to exercise
Number of subjects: 212
Study 30092456 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary disease management programme for patients without contraindications to exercise
Number of subjects: 212
Study 27055521 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2586184 (50-400 mg, oral, twice daily for 12 weeks)
Number of subjects: 50
Study 27055521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral, twice daily for 12 weeks)
Number of subjects: 50
Study 25090449 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-affirmation
Number of subjects: 55
Study 25090449 — intervention group
Group type: COMPARATOR
Intervention: Non-affirmation control
Number of subjects: 55
Study 22808706 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice with target changes in the vertical axis
Number of subjects: 24
Study 22808706 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice with target changes in the horizontal axis
Number of subjects: 24
Study 20575704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single dose)
Number of subjects: 100
Study 20575704 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline (placebo)
Number of subjects: 100